Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Caribou Biosciences, with three buy ratings, one strong-buy rating, and one sell rating. The average 12-month price target is $7.75.
• CRBU shares fell 2.2% to $1.57, near the lower end of their 12-month range of $1.38 to $3.54. Institutional investors own 77.51% of the company.
• Caribou reported a quarterly loss of $0.24 per share, beating estimates for a $0.32 loss, but revenue of $1.50 million came in below the $2.28 million consensus forecast.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $7.75.

Several brokerages have recently commented on CRBU. HC Wainwright boosted their price target on Caribou Biosciences from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Monday, May 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Caribou Biosciences in a research note on Friday, July 17th. Finally, Bank of America decreased their price objective on shares of Caribou Biosciences from $6.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday.

Institutional Trading of Caribou Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in Caribou Biosciences by 80.0% in the 4th quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company's stock valued at $39,000 after purchasing an additional 10,824 shares during the last quarter. CTC Alternative Strategies Ltd. acquired a new stake in shares of Caribou Biosciences during the 1st quarter worth about $29,000. Bronte Capital Management Pty Ltd. purchased a new stake in shares of Caribou Biosciences during the fourth quarter worth about $25,000. Westmount Partners LLC purchased a new stake in shares of Caribou Biosciences during the first quarter worth about $37,000. Finally, Next Capital Management LLC acquired a new position in shares of Caribou Biosciences in the second quarter valued at approximately $35,000. Hedge funds and other institutional investors own 77.51% of the company's stock.

Caribou Biosciences Trading Down 2.2%

Shares of CRBU traded down $0.04 during trading hours on Friday, reaching $1.57. The company had a trading volume of 1,097,561 shares, compared to its average volume of 1,557,463. Caribou Biosciences has a 12-month low of $1.38 and a 12-month high of $3.54. The firm has a 50 day simple moving average of $1.69 and a 200-day simple moving average of $1.84. The company has a market capitalization of $156.21 million, a price-to-earnings ratio of -1.11 and a beta of 2.38.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.08. Caribou Biosciences had a negative net margin of 1,189.14% and a negative return on equity of 84.17%. The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.28 million. Sell-side analysts forecast that Caribou Biosciences will post -1.15 earnings per share for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company's core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source